Oncology Radiopharmaceutical development is accelerating. Preclinical... Radiopharmaceuticals are rapidly becoming one of the most dynamic areas of oncology drug development.
Oncology Hernexeos and what’s next, with Vicky Brown At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent US approval for Hernexeos in NSCLC.
Oncology Day One's big bet on tovorafenib just keeps paying off Now set to be acquired by Servier for $2.5 billion, Day One Bio proves how far a mission-driven biotech with a strong team and good timing can go.
Oncology Sponsored Collaboration & personalisation in rare disease R&D, with AO... For Rare Disease Day, in an AOP Health-sponsored podcast Melissa Fellner, VP of Global Therapeutic Areas, Commercial Operations, discussed their work.
Oncology Daiichi Sankyo gears up for five ADC launches in 2026 On the sidelines of JPM, Daiichi-Sankyo US CEO Ken Keller told pharmaphorum about the company's big year and its long-term strategy in ADCs.
Oncology After 'Year of Harvest', Bayer looks to diversify modalities Bayer Oncology's strategy has led to strong showings in small molecules and radiotherapies. Now they're on the hunt for ADCs, bispecifics, and more.
News Jeito closes 'record' $1.2bn Europe-focused biopharma fund Jeito Capital has closed its second fund, raking in €1bin, which it claims is the largest ever raise for an independent European biopharma fund.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
